Palvella Therapeutics (NASDAQ:PVLA) Upgraded at Jones Trading

Jones Trading upgraded shares of Palvella Therapeutics (NASDAQ:PVLA) to a strong-buy rating in a report published on Monday morning,Zacks.com reports.

PVLA has been the subject of a number of other research reports. Cantor Fitzgerald began coverage on Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an “overweight” rating for the company. TD Cowen began coverage on Palvella Therapeutics in a report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price on the stock. Canaccord Genuity Group restated a “buy” rating and set a $39.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, February 11th. Finally, Scotiabank initiated coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Palvella Therapeutics presently has an average rating of “Buy” and an average price target of $43.50.

Palvella Therapeutics Stock Up 2.4 %

PVLA stock opened at $27.93 on Monday. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $29.27. The company has a market cap of $313.40 million, a PE ratio of -2.31 and a beta of 0.54. The stock’s 50-day moving average is $19.66.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. BML Capital Management LLC purchased a new stake in Palvella Therapeutics in the 4th quarter valued at about $506,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Palvella Therapeutics during the fourth quarter valued at approximately $7,847,000. Cresset Asset Management LLC bought a new stake in Palvella Therapeutics during the fourth quarter worth $251,000. Suvretta Capital Management LLC bought a new position in Palvella Therapeutics in the 4th quarter valued at $8,574,000. Finally, DAFNA Capital Management LLC purchased a new stake in shares of Palvella Therapeutics during the 4th quarter valued at $857,000. 40.11% of the stock is owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.